Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.78
-1.4%		$5.27
$1.70
▼
$6.51
$819.37M0.781.87 million shs666,223 shs
Annexon, Inc. stock logo
ANNX
Annexon
$5.29
+0.6%		$5.35
$2.03
▼
$7.18
$861.81M1.182.51 million shs2.99 million shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$14.02
-0.1%		$15.21
$8.70
▼
$26.18
$830.82M-0.93409,482 shs128,541 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.80
+2.6%		$18.58
$7.78
▼
$34.10
$246.59M1.46174,683 shs116,466 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-1.37%-2.20%+3.21%+27.88%+240.00%
Annexon, Inc. stock logo
ANNX
Annexon
+0.57%-2.22%-18.62%+1.54%+103.46%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-0.07%+4.01%-10.76%-28.65%+41.47%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+2.56%+16.99%-14.02%-38.26%+42.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.78
-1.4%		$5.27
$1.70
▼
$6.51
$819.37M0.781.87 million shs666,223 shs
Annexon, Inc. stock logo
ANNX
Annexon
$5.29
+0.6%		$5.35
$2.03
▼
$7.18
$861.81M1.182.51 million shs2.99 million shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$14.02
-0.1%		$15.21
$8.70
▼
$26.18
$830.82M-0.93409,482 shs128,541 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$16.80
+2.6%		$18.58
$7.78
▼
$34.10
$246.59M1.46174,683 shs116,466 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-1.37%-2.20%+3.21%+27.88%+240.00%
Annexon, Inc. stock logo
ANNX
Annexon
+0.57%-2.22%-18.62%+1.54%+103.46%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-0.07%+4.01%-10.76%-28.65%+41.47%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+2.56%+16.99%-14.02%-38.26%+42.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.13
Buy$11.5098.96% Upside
Annexon, Inc. stock logo
ANNX
Annexon
2.30
Hold$15.33189.86% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.71
Moderate Buy$48.50245.93% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.33
Hold$57.00239.29% Upside

Current Analyst Ratings Breakdown

Latest GLSI, ANNX, DBVT, and ACRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
8/12/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform
7/21/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Underperform$3.00
7/21/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $69.00
7/20/2026
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
7/17/2026
Annexon, Inc. stock logo
ANNX
Annexon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/15/2026
Annexon, Inc. stock logo
ANNX
Annexon
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$11.00 ➝ $25.00
7/13/2026
Annexon, Inc. stock logo
ANNX
Annexon
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
6/30/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$7.83M103.21N/AN/A$0.89 per share6.49
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$0.98 per shareN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$5.64M147.21N/AN/A$2.71 per share5.17
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.21 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.58N/AN/AN/A-921.50%-61.65%-42.41%N/A
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$146.95M-$3.51N/AN/AN/A-3,506.53%-119.33%-84.43%10/28/2026 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%N/A

Latest GLSI, ANNX, DBVT, and ACRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/6/2026Q2 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.15+$0.01-$0.15$1.38 million$1.63 million
7/16/2026Q2 2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.12-$0.60-$0.48-$0.60$0.90 million$0.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
3.46
3.46
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
6.35
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
3.72
3.72
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
2.01

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
4.80%
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.06%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100139.82 million133.11 millionOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60163.84 million146.95 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8059.22 million58.59 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
314.68 million7.12 millionNot Optionable

Recent News About These Companies

Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/greenwich-lifesciences-nasdaqglsi-posts-quarterly-earnings-results-2026-08-11/
Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027
August 10, 2026  |  quiverquant.comQ
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
August 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/10/3341626/0/en/greenwich-lifesciences-extends-lock-up-of-directors-and-officers-to-january-31-2027.html
Greenwich LifeSciences (GLSI) Expected to Post Earnings on Thursday
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/greenwich-lifesciences-glsi-expected-to-post-earnings-on-thursday-2026-08-06/
Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,500 Shares
July 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-glsi-insider-buying-and-selling-2026-07-30/
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,500 Shares
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/greenwich-lifesciences-nasdaqglsi-ceo-snehal-patel-purchases-1500-shares-2026-07-29/
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 1,100 Shares of Stock
July 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-glsi-insider-buying-and-selling-2026-07-29/
Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $14,168.00 in Stock
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/greenwich-lifesciences-nasdaqglsi-ceo-buys-1416800-in-stock-2026-07-28/
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/greenwich-lifesciences-nasdaqglsi-ceo-snehal-patel-purchases-2500-shares-2026-07-28/
Greenwich LifeSciences (NASDAQ: GLSI) - Share Price and Research
July 23, 2026  |  intelligentinvestor.com.auI
HC Wainwright Issues Optimistic Forecast for GLSI Earnings
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-optimistic-forecast-for-glsi-earnings-2026-07-23/
Brokers Set Expectations for GLSI Q1 Earnings
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brokers-set-expectations-for-glsi-q1-earnings-2026-07-22/
Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial
July 22, 2026  |  quiverquant.comQ
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331163/0/en/greenwich-lifesciences-announces-approval-to-expand-flamingo-01-into-the-united-kingdom.html
HC Wainwright Forecasts Strong Price Appreciation for Greenwich LifeSciences (NASDAQ:GLSI) Stock
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-strong-price-appreciation-for-greenwich-lifesciences-nasdaqglsi-stock-2026-07-21/
Greenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial Outlook
July 20, 2026  |  quiverquant.comQ
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329545/0/en/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01.html
Greenwich LifeSciences Announces European Regulatory Review Allows Combined Enrollment of HLA-A*02 and Non-HLA-A*02 Patients in Phase III FLAMINGO-01 Trial
July 16, 2026  |  quiverquant.comQ
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328362/0/en/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-populations-in-flamingo-01.html
Greenwich LifeSciences The Overlooked Need
July 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4922499-greenwich-lifesciences-stock-overlooked-need
Greenwich LifeSciences Shares Up After European Approval for Use of GP2 in Breast Cancer Immunotherapy Trial
July 10, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/greenwich-lifesciences-shares-up-after-european-approval-for-use-of-gp2-in-breast-cancer-immunotherapy-trial-9d758741

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$5.78 -0.08 (-1.37%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$5.82 +0.04 (+0.69%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Annexon stock logo

Annexon NASDAQ:ANNX

$5.29 +0.03 (+0.57%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$5.50 +0.21 (+3.97%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$14.02 -0.01 (-0.07%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$14.04 +0.02 (+0.14%)
As of 08/14/2026 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$16.80 +0.42 (+2.56%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$16.81 +0.01 (+0.04%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas